Clinical trials: sponsored by University Health Network, Toronto
Cutaneous Melanoma, Melanoma Stage IV
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
Clear-Me is a biomarker-driven phase II study that tests whether the combination anti- lymphocyte-activation gene-3 (LAG3)/anti-programmed cell death protein 1(PD-1) inhibition Bristol-Myers Squibb (BMS986213) is superior to…
- Conditions
- Cutaneous Melanoma, Melanoma Stage IV, Mucosal Melanoma
- Trial name
- ClearMe (NCT06319196)
- Testing
- Opdualag, Nivolumab
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- University Health Network, Toronto
Autonomic Dysfunction
Cervicothoracic Sympathetic Block Evaluation for Post COVID Condition
Post-COVID Condition (PCC) affects roughly 2.1 million Canadians, carrying an annual economic burden of CAD $7.8-50.6 billion. It presents across multiple organ systems with symptoms including fatigue, brain fog, palpitations…
- Trial name
- CeASE (NCT07468604)
- Testing
- 5 mL of 0.25% bupivacaine with epinephrine (1:200,000)
- Where
- 2 sites in Canada
- Volunteers
- 78 people
- Sponsor
- University Health Network, Toronto
Post-Operative Prostate Cancer
Comparing Moderately and Ultra Hypofractionated Radiation Treatments for Post-operative Prostate Cancer
This is a multi-institution, randomized, non-inferiority Phase II trial comparing external beam radiotherapy delivered as 54 Gy in 20 fractions to prostate bed +/- 44 Gy in 20 fractions to pelvic lymph nodes delivered daily with…
- Trial name
- AMPORA (NCT06409910)
- Testing
- Radiotherapy
- Where
- 3 sites in Canada
- Volunteers
- 204 people
- Sponsor
- University Health Network, Toronto
Hereditary Cancer Syndrome
CfDNA in Hereditary And High-risk Malignancies 2
The goal of this study is to understand the performance of an experimental blood test that aims to detect early tumors in patients with hereditary cancer syndromes.
- Trial name
- CHARM2 (NCT06726642)
- Testing
- Cell-free DNA analysis
- Where
- 8 sites in Canada
- Volunteers
- 1,000 people
- Sponsor
- University Health Network, Toronto
Bladder Cancer, Bladder Urothelial Carcinoma
Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)
Upper tract urothelial cancer (UTUC) is cancer in the lining of the kidney or ureter (the tube that drains the kidney). This type of cancer is rare and as a result, there are only a few studies that have looked at it.
- Trial name
- NAUTICAL (NCT04574960)
- Testing
- Gemcitabine, Cisplatin, Carboplatin
- Where
- 2 sites in Canada
- Volunteers
- 14 people
- Sponsor
- University Health Network, Toronto
Major Depressive Disorder, Suicide
i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
Approximately four thousand Canadians die by suicide every year, and suicide is the second leading cause of death in youth and young adults (15-34 years).
- Conditions
- Major Depressive Disorder, Suicide, Treatment Resistant Depression
- Trial name
- Ket-CBT (NCT06480500)
- Testing
- Ketamine hydrochloride, i-CBT (Internet-based Cognitive Behavioural Therapy), Midazolam Hydrochloride
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- University Health Network, Toronto
Chronic Low Back Pain (CLBP), Nociplastic Pain
PRT for Chronic Low Back Pain
The goal of this clinical trial is to learn whether Pain Reprocessing Therapy (PRT) is a feasible and acceptable treatment to complete for working-age adults (ages 18-65) with chronic low back pain.
- Trial name
- NCT07696741
- Testing
- Pain Reprocessing Therapy, Monitoring and Education
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
All Solid Tumors
Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients
This study is designed to assess the safety, tolerability and engraftment (cumulative relative abundance) of MET-4 strains when given in combination with immune checkpoint inhibitors (ICIs).
- Trial name
- MET4-IO (NCT03686202)
- Testing
- MET-4
- Where
- Canada
- Volunteers
- 65 people
- Sponsor
- University Health Network, Toronto
Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
This is a phase 2, single-centre, randomized, multi-cohort trial of subjects with advanced Mismatch Repair Proficient Colorectal Cancer (MMRp-CRC), Pancreatic Adenocarcinoma (PA), and Leiomyosarcoma (LMS).
- Conditions
- Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma
- Trial name
- DAPPER (NCT03851614)
- Testing
- Durvalumab, Olaparib, Cediranib
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- University Health Network, Toronto
Solid Tumor
Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
This is a single-center, investigator-initiated, non-interventional study evaluating the role of the intestinal microbiome and autoimmune panels as a predictor for developing ≥ Grade 2 CTCAE v5.0 immune-related adverse event…
- Trial name
- INSPECT-IO (NCT04107311)
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto
Pulmonary Hypertension
PET/MR Pre- and Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation
Radiotherapy (RT) is a well-known and established therapy or adjuvant therapy for the treatment of thoracic cancer It uses a high energy radiation from x-rays, gamma rays and other charged particles that assist in damaging the…
- Trial name
- NCT04901884
- Testing
- PET/MR with 18F-FDG
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC
This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally…
- Trial name
- MERIDIAN (NCT05414032)
- Testing
- AZD2936
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- University Health Network, Toronto
Bleeding, Platelets
Autologous Cold-stored Apheresis Platelets
The Auto-PLTS Study is a single-centre trial performed at Toronto General Hospital (TGH) that uses a randomized, patient preference design.
- Conditions
- Bleeding, Platelets, Cardiopulmonary Bypass, Cardiac Surgery
- Trial name
- Auto-PLTS (NCT07064954)
- Testing
- Autologous Cold-Stored Platelets, Allogeneic Room Temperature-Stored Platelets (Standard of Care)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer, Liver Metastases
Living Donor Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases
Patients with unresectable liver metastases (LM) from colorectal cancer (CRC)have a poor prognosis. In patients with resectable disease, surgery offers a distinct survival benefit.
- Trial name
- NCT02864485
- Testing
- live donor liver transplantation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Cholangiocarcinoma, Intrahepatic
Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma
Diagnosis of intrahepatic cholangiocarcinoma (iCCA) is an increasingly common form of primary liver cancer, but patients with this diagnosis are not currently eligible for LT.
- Trial name
- NCT04195503
- Testing
- Liver Transplantation
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Squamous Cell Cancer of Head and Neck, Triple Negative Breast Cancer
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
This is a phase 2 study whose main purpose is to evaluate gene changes and immune biomarkers in patients with solid tumors during treatment with pembrolizumab and in relation to response to treatment.
- Conditions
- Squamous Cell Cancer of Head and Neck, Triple Negative Breast Cancer, Epithelial Ovarian Cancer, Malignant Melanoma
- Trial name
- INSPIRE (NCT02644369)
- Testing
- Pembrolizumab
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Locoregionally-advanced Oropharyngeal Squamous Cell Carcinoma
Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma
This is a minimal risk feasibility study involving the analysis of patient samples and does not involve any therapeutic intervention.
- Trial name
- ROMA LA-OPSCC (NCT03759730)
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- University Health Network, Toronto
Multiple Myeloma
PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)
Multiple myeloma is a disease mainly located in participants bones. Usually a participants physician arrives at this diagnosis by doing blood tests and ordering standard of care imaging tests (18F-FDG PET/CT and maybe additional…
- Trial name
- NCT06871176
- Testing
- [68Ga]Ga-PentixaFor
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
The BeeHive study is an investigator-initiated, single center, open-label phase II clinical trial that is designed to conduct a comprehensive multiomic biomarker evaluation across two single-arm cohorts to elucidate mechanisms of…
- Trial name
- BeeHive (NCT07408063)
- Testing
- GSK5764227, Dostarlimab
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Testis Cancer
miRNA to Guide Appropriate Intervention of Small Testis Masses
This study aims to determine, for the first time, if miRNA-371a-3p can be used as an accurate biomarker to identify which small (≤ 2cm) testicular masses are malignant and aid in clinical decision-making to offer surgery or…
- Trial name
- miRSTM (NCT07852871)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto